GMJ Technologies, Inc. is a Seattle-based company developing analytical solutions to revolutionize the proteomics and protein-drugs analytical workflows with proprietary microanalytical technologies. The company operates in the biotechnology sector.
GMJ Technologies' flagship product is the CeMAX UV capillary electrophoresis separation system coupled with optical-MS detection, which offers improved robustness, sensitivity, and reduced reagent consumption for protein characterization. The company's business functions primarily through R&D of novel technologies and related applications, prototype development for manufacturing through contract or strategic partners, and services to grow and retain customers.
The company has 3 total employees and is backed by investors including Life Science Washington, National Institutes of Health, U.S. National Science Foundation, UW CoMotion, and the University of Washington.
Facts compiled by Executive Moves from publicly available news and press releases on 10 June 2026. Spotted an inaccuracy? Email us and we'll review within 1 business day.
To upgrade to a Premium Profile reach out to us at info@executive-moves.com.
Are you on the GMJ Technologies team?
This is a Light company page, auto-generated from public news coverage. Claim it to verify the company description, add logo and links, and control how your organisation is represented on Executive Moves.
Claim this company →
